Gougerot-Sjogren-like syndrome under PD-1 inhibitor treatment

Teyssonneau, Diego; Cousin, Sophie; Italiano, Antoîne

doi:10.1093/annonc/mdx531

Cited by 18 publications

(7 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As SS is immune related, we can speculate that oral corticosteroids may benefit patients with ICI-induced SS. However, proposing oral corticosteroids for grade 2-3 SS seems premature (Table 2) [6][7][8][9][10]. In our series, basic oral care [5] without oral corticosteroids led to a mild improvement in almost half of our patients.…”

mentioning

confidence: 62%

Sicca Syndrome Induced by Immune Checkpoint Inhibitor Therapy: Optimal Management Still Pending

et al. 2019

View full text Add to dashboard Cite

show abstract

mentioning

confidence: 62%

Sicca Syndrome Induced by Immune Checkpoint Inhibitor Therapy: Optimal Management Still Pending

et al. 2019

View full text Add to dashboard Cite

show abstract

“…A patient with metastatic parotid carcinoma developed a sicca syndrome associated with a skin rash on both hands that was identified as Gourgerot-Sjogren like syndrome [ 41 ].…”

Section: Resultsmentioning

confidence: 99%

Musculoskeletal and Rheumatic Diseases Induced by Immune Checkpoint Inhibitors: A Review of the Literature

Benfaremo

Manfredi

Luchetti

et al. 2018

CDS

View full text Add to dashboard Cite

Background: Immune checkpoint inhibitors are a new promising class of antitumor drugs that have been associated with a number of immune-related Adverse Events (AEs), including musculoskeletal and rheumatic disease.Methods: We searched Medline reviewing reports of musculoskeletal and rheumatic AEs induced by immune checkpoint inhibitors.Results: Several musculoskeletal and rheumatic AEs associated with immune checkpoint inhibitors treatment are reported in the literature. In particular, arthralgia and myalgia were the most common reported AEs, whereas the prevalence of arthritis, myositis and vasculitis is less characterized and mainly reported in case series and case reports. Other occasionally described AEs are sicca syndrome, polymyalgia rheumatica, systemic lupus erythematosus and sarcoidosis.Conclusion: Newly induced musculoskeletal and rheumatic diseases are a frequent adverse event associated with immune checkpoint inhibitors treatment

show abstract

“…An additional 17 patients with de novo sicca symptoms have been published in small series [4, 14, 16, 32, 38, 67] (Table 1). The median age of these patients was 63 (36–81) years, 53% were male, 71% had melanoma and 88% received anti-PD-1/PD-L1 (single agent or combination ICI).…”

Section: Common Rheumatic Immune-related Adverse Eventsmentioning

confidence: 99%

Frequency and distribution of various rheumatic disorders associated with checkpoint inhibitor therapy

Abdel-Wahab

Suarez‐Almazor

2019

Rheumatology

View full text Add to dashboard Cite

Immune checkpoint inhibitors have advanced the treatment paradigm of various cancers, achieving remarkable survival benefits. However, a myriad of immune-related adverse events (irAE) has been recognized in almost every organ system, presumably because of persistent immune system activation. Rheumatic symptoms such as arthralgia or myalgia are very common. More specific irAE are increasingly being reported. The most frequent ones are inflammatory arthritis, polymyalgia-like syndromes, myositis and sicca manifestations. These rheumatic irAE can develop in ∼5–10% of patients treated with immune checkpoint inhibitors, although true incidence rates cannot be estimated given the lack of prospective cohort studies, and likely underreporting of rheumatic irAE in oncology trials. In this review, we will provide a summary of the epidemiologic data reported for these rheumatic irAE, until more robust prospective longitudinal studies become available to further define the true incidence rate of rheumatic irAE in patients receiving these novel cancer therapies.

show abstract

Gougerot-Sjogren-like syndrome under PD-1 inhibitor treatment

Cited by 18 publications

References 2 publications

Sicca Syndrome Induced by Immune Checkpoint Inhibitor Therapy: Optimal Management Still Pending

Sicca Syndrome Induced by Immune Checkpoint Inhibitor Therapy: Optimal Management Still Pending

Musculoskeletal and Rheumatic Diseases Induced by Immune Checkpoint Inhibitors: A Review of the Literature

Frequency and distribution of various rheumatic disorders associated with checkpoint inhibitor therapy

Contact Info

Product

Resources

About